The PE Ratio as of November 2024 (TTM) for Zai Lab Limited (ZLAB) is -9.44

According to Zai Lab Limited’s latest financial reports and current stock price. The company's current PE Ratio is -9.44. This represents a change of 10.98% compared to the average of -8.51 of the last 4 quarters.

Zai Lab Limited (ZLAB) Historical PE Ratio (quarterly & annually)

How has ZLAB PE Ratio performed in the past?

The mean historical PE Ratio of Zai Lab Limited over the last ten years is -23.24. The current -9.44 PE Ratio has changed 3.96% with respect to the historical average. Over the past ten years (40 quarters), ZLAB's PE Ratio was at its highest in in the December 2018 quarter at -4.82. The PE Ratio was at its lowest in in the December 2020 quarter at -38.69.

Zai Lab Limited (ZLAB) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Zai Lab Limited PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Zai Lab Limited (ZLAB) Average PE Ratio

How has ZLAB PE Ratio performed in the past?

The current PE Ratio of Zai Lab Limited (ZLAB) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Zai Lab Limited (ZLAB) PE Ratio vs. Peers

How is ZLAB’s PE Ratio compared to its peers?

Zai Lab Limited’s PE Ratio is less than C4 Therapeutics, Inc. (-2.80), less than Erasca, Inc. (-4.79), less than Cullinan Oncology, Inc. (-5.10), greater than Legend Biotech Corporation (-21.42), greater than Seagen Inc. (-100.71), greater than Alnylam Pharmaceuticals, Inc. (-94.78), greater than Ascendis Pharma A/S (-16.63), less than Roivant Sciences Ltd. (0), less than Krystal Biotech, Inc. (1.92), less than Prometheus Biosciences, Inc. (104.40), greater than Akero Therapeutics, Inc. (-57.28), greater than Apellis Pharmaceuticals, Inc. (-9.58), greater than PTC Therapeutics, Inc. (-15.24), less than Blueprint Medicines Corporation (-7.34), greater than Intercept Pharmaceuticals, Inc. (-46.60), greater than Madrigal Pharmaceuticals, Inc. (-91.78), greater than null (-14.57),

Build a custom stock screener for Zai Lab Limited (ZLAB) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Zai Lab Limited using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Zai Lab Limited (ZLAB) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Zai Lab Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.